Laura Shawver - Aug 1, 2023 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Director
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Aug 1, 2023
Transactions value $
-$321,996
Form type
4
Date filed
8/3/2023, 06:03 PM
Previous filing
Jul 7, 2023
Next filing
Aug 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $23.8K +18.7K +8.9% $1.27* 229K Aug 1, 2023 Direct
transaction SPRY Common Stock Sale -$135K -18.7K -8.17% $7.19 210K Aug 1, 2023 Direct F1, F2
transaction SPRY Common Stock Options Exercise $46.1K +36.3K +17.25% $1.27* 247K Aug 2, 2023 Direct
transaction SPRY Common Stock Sale -$257K -36.3K -14.71% $7.09 210K Aug 2, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -18.7K -18.17% $0.00 84.3K Aug 1, 2023 Common Stock 18.7K $1.27 Direct F4
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -36.3K -43.05% $0.00 48K Aug 2, 2023 Common Stock 36.3K $1.27 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.11 to $7.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.95 to $7.23, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F4 Immediately exercisable.